+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease

Infection and Immunity 32(2): 534-541

Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease

The results of the present investigation indicate a simple approach to the development of a single-vaccine formula which may ultimately be used to confer protection against both cholera and certain types of Escherichia coli diarrheal disease in humans and domestic animals. The design of the vaccine is based on the well-documented ability of cholera antitoxin to neutralize both cholera and heat-labile E. coli enterotoxins (CT and LT, respectively) and on the ability of killed E. coli to enhance the immune response to cholera toxoid and, possibly, to conventional cholera vaccine as well. Evidence presented shows that a parenterally administered E. coli vaccine, prepared from an LT-only enterotoxigenic strain, reproducibly elevated rabbit antitoxin responses to cholera toxoid and that such responses correlated with dramatic protection against live cholera vibrios and the homologous E. coli strain in the rabbit ligated loop model of diarrheal disease. The results show also that cholera vaccine acted to suppress the rabbits' immune response to the cholera toxoid and E. coli vaccine formula, even though all three antigens combined still provided significant protection against live organism challenge. On the basis of data presently available, the vaccine formula would be composed simply of cholera toxoid and E. coli vaccine, but may also include cholera vaccine. Since it has already been established that cholera toxoid and cholera vaccine are each safe for human use, additional vaccine development would require investigation of the safety of E. coli vaccine, alone and in combination with the other components.

Accession: 005132162

PMID: 7019073

Related references

Rappaport R.S.; Bonde G., 1982: Prospects for the development of a vaccine against cholera and escherichia coli diarrheal disease. Robbins, J B , J C Hill And J C Sadoff (Ed ) Seminars in Infectious Disease, Vol 4 Bacterial Vaccines; International Symposium, Sept 15-18, 1980 Xxxiv+461p Thieme-Stratton, Inc : New York, N Y , Usa; Georg Thieme Verlag: New York, N Y , Usa; Stuttgart, West Germany Illus P89-96

Anonymous, 1956: Experimental diarrheal disease of human volunteers due to Escherichia coli; In Epidemic and endemic diarrheal diseases of the infant

Boedeker E.; Wolf M.; Taylor D.; Hyams K.; Maneval D.; Levine M.; Tamura K.; Wilson R.; Echeverria P., 1992: Characterization of enterotoxigenic escherichia coli etec isolated from us soldiers with diarrheal disease during operation desert shield implications for vaccine development. Gastroenterology 102(4 PART 2): A597

Ferguson, W.W., 1956: Experimental diarrheal disease of human volunteers due to Escherichia coli. Annals of the New York Academy of Sciences 66(1): 71-77

Svennerholm, A-Mari., 2011: From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. It was shown earlier that immune responses against cholera toxin (CT) as well as Vibrio cholerae lipopolysaccharide (LPS) or whole bacterial cells (WC) were protective and that these different antibody specificities co-operated synergistically for...

Gennaro, M.L.; Greenaway, P.J.; Broadbent, D.A., 1982: Expression of cloned cholera enterotoxin gene in Escherichia coli and possibilities of vaccine development. Lancet 1(8283): 1239-1240

Dasgupta, U.; Guhathakurta, I.; Das, J., 1988: Excretion of cholera toxin from Escherichia coli: a potential oral vaccine for cholera. Escherichia coli strain N100 has been mutagenized by transposon mutagenesis and mutants with a cell surface leaky phenotype have been isolated. The mutant designated as E. coli N100::Tn5 excreted periplasmic proteins like ribonuclease and alkaline...

Darsley, M.J.; Chakraborty, S.; DeNearing, B.; Sack, D.A.; Feller, A.; Buchwaldt, C.; Bourgeois, A.Louis.; Walker, R.; Harro, C.D., 2013: The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. An oral, live attenuated, three-strain recombinant bacterial vaccine, ACE527, was demonstrated to generate strong immune responses to colonization factor and toxin antigens of enterotoxigenic <I>Escherichia coli</I> (ETEC) in human vol...

Kim, B.H.; Kim, Y.H.; Jean, Y.H.; Lee, O.S.; Choi, C.U.; Kim, C.K.; An, S.H.; Rhee, J.C., 1990: Studies on the development of hog cholera live vaccine 3. field application of experimental hog cholera vaccine. An experimental live vaccine derived from Suri strain of hog cholera virus was tested for its safety in SPF and commercial pigs and for its immunogenicity in field trials. SPF piglets given either E- (suri strain) or LOM BK+ virus vaccine did not...

Holmgren J.; Svennerholm A M., 1985: Vaccine development for the control of cholera and related toxin induced diarrheal diseases. Evered, D And J Whelan (Ed ) Ciba Foundation Symposium, No 112 Microbial Toxins And Diarrhoeal Disease; London, England, July 10-12, 1984 Ix+286p The Ciba Foundation: London, England (Dist in The Usa By Ciba Pharmaceutical Co : Newark, N J , Usa) Illus 242-270